Drug intelligence / Profile preview

LY4226695

Development stage: Phase 1
Lead developer: Eli Lilly
Administration: Subcutaneous, Intravenous

Overview

LY4226695 is an investigational drug candidate being developed by Eli Lilly and Company. It is currently undergoing Phase 1 clinical evaluation in a single-ascending and multiple-ascending dose study designed to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants, including specific cohorts for Chinese and Japanese participants. The asset is administered via subcutaneous or intravenous routes. As of early clinical development, the specific biological target, mechanism of action, and primary therapeutic indications for LY4226695 have not been publicly disclosed.

Beyond the preview

Go deeper on LY4226695.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4226695.

Explore the full profile